

2021 Independent Medical Education Call for Grant Notification

Issue Date: February 26, 2021

The *Independent Medical Education team at Genentech, a member of the Roche Group*, invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Call for Grants Notification (CGN) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

Purpose: As part of Genentech's scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

Notification: Genentech CGNs are made available through our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>) along with the websites for the Alliance for Continuing Education in the Health Professions (ACEhp) and the Society for Academic Continuing Medical Education (SACME). *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

Terms and Conditions

1. All grant applications received in response to this CGN will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on <http://funding.gene.com>)
2. This CGN does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this CGN.
4. For compliance reasons, and in fairness to all providers, all communications about this CGN must come exclusively to Genentech's department of Medical Education and Research Grants. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this CGN may result in a denial.

Instructions

Eligibility Criteria	<ul style="list-style-type: none">• U.S. based education provider• Registered account in gFRS• Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)
Geographical Scope	<ul style="list-style-type: none">• Educational initiatives must be U.S.-based only

Submission Directions	Application Process	Deadlines
Step 1	Providers who meet the eligibility criteria and are interested in submitting a response to this CGN will have 3 weeks to complete a brief Executive Summary through the following link at https://forms.gle/HY4QAwNgRA5jSFd4A	March 19, 2021
Step 2	After 2 weeks, respective Genentech Medical Education Managers will notify (via email) those providers whose Executive Summaries were selected for further review.	April 2, 2021
Step 3	Those providers who receive notification of potential interest will have 3 weeks to submit full grant application(s) online through gFRS. Further instructions will be provided in the email notification.	April 23, 2021
Step 4	Notification of final decisions will occur via email	May 7, 2021

Additional Considerations

Provider(s) who are awarded grants are encouraged but not required to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or patient outcomes improvement as a result of the educational activity.
3. Summarize (through written analysis) the provider's understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

Currently Available CGN Focus Area:

Focus	Opportunity
<p>Therapeutic Area: Neurology</p> <p>Learning Audience: General Neurologists</p> <p>Primary Care Providers</p> <p>Advanced Practice Providers (Physician Assistants/Nurse Practitioners)</p> <p>Pharmacists</p> <p>Nurses</p> <p>Support Available: Up to \$250,000</p> <p>Knowledge- and Competence-based National and Regional Education <i>(Understanding & addressing national or local gaps and emerging data)</i></p>	<p>The care continuum for patients with neurologic conditions has dramatically changed since the beginning of the COVID-19 pandemic. There is now an increased need for home-administration of therapies and remote monitoring of patient health and well-being. The shift to virtual visits is likely to stay somewhat consistent even post-pandemic due to the benefits seen in the use of telemedicine.¹</p> <p>Current barriers for individual healthcare providers in utilizing telemedicine include lack of knowledge of best practices in conducting virtual neurological exams, examination limitations for various neurologic conditions, learning how to incorporate remote visits and e-consults into daily practice, increased preparation for patient visits, and increased physical drain.^{2,3}</p> <p>A critical need exists to educate general neurologists and allied health professionals on how to address these barriers and implement best practices in telemedicine.^{4,5}</p> <p>References:</p> <ol style="list-style-type: none"> 1. Klein, B., Busis, N. COVID-19 is catalyzing the adoption of teleneurology. <i>Neurology</i> 2020;94:903-904. 2. Laskowski, ER, Johnson, SE, Shelerud, RA, et al. The Telemedicine Musculoskeletal Examination. <i>Mayo Clin Proc.</i> 2020;95:1715-1731. 3. Al Hussona M, Maher M, Chan D, et al. The virtual neurologic exam: Instructional videos and guidance for the COVID-19 era. <i>Can J Neurol Sci</i> 2020;1-6. 4. Guzik, A., Switzer, J. Teleneurology is neurology. <i>Neurology</i> 2020;94:16-17. 5. Moss, H., Lai, K., Ko, M., Survey of Telehealth Adoption by neuro-ophthalmologists during the COVID-19 pandemic: benefits, barriers, and utility. <i>Journal of Neuro-Ophthalmology</i> 2020;00:1-10.